Celcuity launches REVTORPYK for HR+/HER2- advanced breast cancer
The gedatolisib-based therapy is now available in the US following its July 2026 FDA approval, Celcuity said on September 30, 2026.
SEC filing
Latest
1 story
Sign inSign in1 story
The gedatolisib-based therapy is now available in the US following its July 2026 FDA approval, Celcuity said on September 30, 2026.
SEC filing